By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Life Science Nation (LSN) team is gearing up for next year’s highly anticipated RESI JPM conference in San Francisco. With a curated program featuring 7 dynamic panels, attendees can expect to gain the latest perspectives on early-stage life science and healthcare investment opportunities. The investor panels at RESI JPM will be Corporate VC, Women’s Health, Medical Device, Pediatrics, Big Pharma, Oncology Innovation, and Longevity Investment.
LSN has assembled diverse panelists representing various investment groups, including corporate venture capitalists, women’s health advocates, early-stage therapeutics, and oncology innovation leaders. These experts will share their strategies, approaches to early-stage investment, perspectives on industry landscapes, insights into startup ecosystems, and much more. As a truly global conference, RESI JPM will also welcome numerous international investors and cross-border investment groups, fostering dynamic discussions and facilitating valuable networking opportunities.
The primary goal of the RESI panels is to facilitate constructive conversations between investors and fundraising CEOs. Attendees can expect to receive tactical advice on effective capital-raising strategies and partnership acquisition, empowering companies to navigate the fundraising journey successfully. These must-attend panels present an unparalleled opportunity for founders and CEOs to engage directly with investors, expand their networks, and gain invaluable insights to propel their businesses forward.
Join the panelists below at RESI JPM 2025!
 Jesus Baena Director BD&L Oncology Novartis |
 Elizabeth Bailey Managing Partner Foreground Capital |
 Joshua Barney Investor Barrington Angels |
 Mel Barsky Managing Partner, CABHI Ventures Centre for Aging + Brain Health Innovation |
 Sebright Chen Chairman and CEO Summer Atlantic Capital |
 Jeff Chu Managing Partner Features Capital |
 David Cole CEO TOO Futures |
 Brittany Connors Director of Investor Relations SBIR/NCI/NIH |
 Yaron Daniely General Partner aMoon Fund |
 Tanja Dowe Managing Director Angelini Ventures |
 Gary Gershony Partner BayMed Venture Partners |
 Tom Gibbs Sr. Investment Director Debiopharm Innovation Fund |
 Friedemann Janus SVP Head of Regional BD & Licensing, Open Innovation and Divestitures Bayer |
 MyPhuong Le General Partner Aquillius Ventures |
 Jin Lee Investor Oxford Angel Fund |
 Darwin Ling Founder & General Partner Good AI Capital |
 Hannah Mamuszka Managing Partner 10Edison Capital |
 Jeffrey Moore President MP Healthcare Venture Management |
 Nick Naclerio Founder & Managing Partner Illumina Ventures |
 Andrew Offer Managing Director & CFO Scientific Health Development Partners |
 Sonal Panda Principal Tau Ventures |
 Soyoung Park General Partner 1004 Venture Partners |
 John Parker Founder & Managing Director Springhood Ventures |
 John Pennett Angel Investor Mid Atlantic Bio Angels |
 Diana Pignalosa Head of Strategic Partnering Debiopharm International S.A. |
 Preetha Ram Managing Partner Pier 70 Ventures |
 Marc Ramis Managing Partner Montana Impact Fund |
 Rachel Strick Director, BD & Licensing AbbVie |
 Leah Villegas Managing Partner Aquillius Ventures |
 Tad Weems Managing Director Agilent Technologies |
 Lu Zhang Founder and Managing Partner Fusion Fund |
 Jackie Zou Vice President, BD Myriad Genetics |
 Sa'ar Yaniv Principal, BD and Corporate Strategy for the Life Sciences Allagi LifeSci |
 Tomer Stavitsky Executive Corporate Development / BD Advisor Tomer Stavitsky Consulting & Advisory |
Next Phase Newsletter 
Leave a comment